HomeCompareICVX vs STAG

ICVX vs STAG: Dividend Comparison 2026

ICVX yields 13.06% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICVX wins by $28.9K in total portfolio value
10 years
ICVX
ICVX
● Live price
13.06%
Share price
$15.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.3K
Annual income
$2,943.04
Full ICVX calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — ICVX vs STAG

📍 ICVX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICVXSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICVX + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICVX pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICVX
Annual income on $10K today (after 15% tax)
$1,110.39/yr
After 10yr DRIP, annual income (after tax)
$2,501.58/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, ICVX beats the other by $2,108.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICVX + STAG for your $10,000?

ICVX: 50%STAG: 50%
100% STAG50/50100% ICVX
Portfolio after 10yr
$32.8K
Annual income
$1,702.87/yr
Blended yield
5.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

ICVX
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
Price Target
$27.00
+76.4% upside vs current
Range: $27.00 — $27.00
Altman Z
22.6
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICVX buys
0
STAG buys
0
No recent congressional trades found for ICVX or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICVXSTAG
Forward yield13.06%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$47.3K$18.3K
Annual income after 10y$2,943.04$462.70
Total dividends collected$21.0K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$27.00$45.00

Year-by-year: ICVX vs STAG ($10,000, DRIP)

YearICVX PortfolioICVX Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$12,006$1,306.34$10,665$345.38+$1.3KICVX
2$14,313$1,465.82$11,365$358.01+$2.9KICVX
3$16,948$1,633.07$12,099$370.76+$4.8KICVX
4$19,941$1,807.22$12,870$383.63+$7.1KICVX
5$23,324$1,987.33$13,678$396.60+$9.6KICVX
6$27,129$2,172.42$14,526$409.67+$12.6KICVX
7$31,390$2,361.53$15,413$422.82+$16.0KICVX
8$36,141$2,553.64$16,343$436.05+$19.8KICVX
9$41,419$2,747.79$17,315$449.35+$24.1KICVX
10$47,261$2,943.04$18,332$462.70+$28.9KICVX

ICVX vs STAG: Complete Analysis 2026

ICVXStock

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Full ICVX Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this ICVX vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICVX vs SCHDICVX vs JEPIICVX vs OICVX vs KOICVX vs MAINICVX vs PLDICVX vs EQRICVX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.